Clenbuterol Overview, Dosing & Safety | Peptide Database

Clenbuterol (Clen)

Beta-2 Agonist | Thermogenic Fat Loss

Community Research

Join others researching Clenbuterol — share findings, ask questions, and learn from real experiences

Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist originally developed for the treatment of asthma and other respiratory conditions. It is approved as a bronchodilator in many countries throughout Europe, Latin America, and Asia, but has never been approved for human use in the United States, where it is only approved for veterinary use in horses (Ventipulmin). In the context of bodybuilding and physique sports, clenbuterol is widely used as a thermogenic agent during cutting phases to accelerate fat loss while preserving lean muscle mass. Its stimulatory effects on the sympathetic nervous system increase basal metabolic rate, core body temperature, and lipolysis. Unlike anabolic steroids, clenbuterol does not directly promote muscle growth in humans at typical doses, though animal studies have demonstrated significant anabolic effects in livestock, which led to its controversial use in meat production in some countries.

Clenbuterol selectively binds to beta-2 adrenergic receptors on cell surfaces, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) in adipose tissue, directly stimulating lipolysis and the release of free fatty acids for oxidation. In smooth muscle tissue, beta-2 activation causes relaxation of bronchial airways, which accounts for its therapeutic use in asthma. Clenbuterol also stimulates mitochondrial uncoupling and increases thermogenesis, raising basal metabolic rate by an estimated 5-10%. Additionally, clenbuterol has mild anti-catabolic properties in humans, potentially reducing muscle protein breakdown during caloric restriction through beta-2 receptor-mediated inhibition of the ubiquitin-proteasome pathway. A significant limitation is the downregulation of beta-2 receptors with continuous use, typically occurring within 2-3 weeks, which diminishes the thermogenic effect and necessitates cycling protocols or co-administration of ketotifen (an antihistamine that upregulates beta receptors).

Molecular Data

Research Indications

Accelerates fat loss during caloric restriction by increasing metabolic rate and stimulating lipolysis. Most commonly used in the final weeks of a cutting phase when body fat is already relatively low and progress has stalled.

Anti-catabolic properties help reduce muscle protein breakdown during aggressive caloric deficits. Effect is modest in humans compared to the dramatic anti-catabolic effects observed in animal studies.

Widely used in bodybuilding and physique competition preparation to achieve very low body fat levels. Typically deployed in the final 4-8 weeks before competition alongside other compounds.

Approved in many countries (not the US) as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease. Relaxes bronchial smooth muscle and improves airflow.

Dosing Protocols

Clenbuterol is administered orally in tablet form, typically available in 20 mcg or 40 mcg tablets. It is rapidly absorbed from the gastrointestinal tract with high oral bioavailability (~70-80%). Peak plasma concentrations are reached within 2-3 hours of ingestion. The long half-life of approximately 36 hours means that once-daily dosing is sufficient, though some users split the dose to reduce peak-related side effects. Morning administration is strongly recommended to minimize insomnia.

Standard Cutting - 2 Weeks On / 2 Weeks Off

20 mcg/day ramping to 80-120 mcg/day

Once daily (morning)

Oral

Continuous Protocol with Ketotifen

Conservative / Female Protocol

20 mcg/day ramping to 40-80 mcg/day

Protocol Variations

Multiple approaches exist - compare before choosing

Different sources recommend different protocols for this peptide. Review each approach and consider your goals, tolerance, and experience level before choosing.

2 Weeks On / 2 Weeks Off

Source: Traditional Cycling Protocol

"Alternating periods of use and rest to prevent beta-2 receptor downregulation and maintain thermogenic efficacy without ancillary compounds."

The most widely used clenbuterol protocol. Users ramp the dose up over the first few days, maintain the peak dose for the remainder of two weeks, then discontinue completely for two weeks to allow beta-2 receptors to resensitize. During off weeks, some users substitute ephedrine/caffeine as an alternative thermogenic. This cycle is repeated for the duration of the cutting phase.

Key Points

No ancillary compounds required (no ketotifen)

Regular 2-week breaks allow cardiovascular recovery

Each on-cycle begins at full dose (no re-ramping needed in subsequent cycles for experienced users)

Thermogenic effect diminishes noticeably by day 10-14

Off periods may slow fat loss progress temporarily

Dosing Schedule

Continuous with Ketotifen

Source: Extended Use Protocol

"Co-administration of ketotifen to upregulate beta-2 receptors allows for longer continuous use without the loss of thermogenic efficacy that occurs with clenbuterol alone."

Ketotifen is an antihistamine (H1 receptor antagonist) that has been shown to upregulate beta-2 adrenergic receptors. By adding ketotifen at 1-2 mg nightly starting in the second week, users can extend clenbuterol cycles to 6-8 weeks continuously. This avoids the off periods of the traditional protocol and may produce more consistent fat loss over the cycle duration. The main drawback is that ketotifen causes drowsiness and increased appetite in some users.

Requires ketotifen (1-2 mg nightly) as an ancillary compound

Allows continuous use for 6-8 weeks without receptor desensitization

More consistent thermogenic output over the full cycle duration

Ketotifen may cause drowsiness (take before bed) and increased appetite

Overall clenbuterol exposure is higher, which may increase cardiac risk

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Tremors and shaking (especially hands) - most pronounced in the first 3-5 days

Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)

Insomnia and sleep disturbance, particularly with afternoon or evening dosing

Muscle cramps (calves, forearms, back) due to taurine depletion

Increased sweating and elevated body temperature

Headaches, particularly during dose ramp-up

Nervousness, anxiety, and restlessness

Increased blood pressure

Stop Signs - Discontinue if:

Irregular or rapid heartbeat, palpitations, or chest pain

Severe difficulty breathing or shortness of breath at rest

Persistent nausea, vomiting, or feeling of impending doom

Severe, unrelenting muscle cramps unresponsive to supplementation

Dizziness, fainting, or near-syncope

Signs of allergic reaction: rash, swelling, difficulty swallowing

Contraindications

Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia

Uncontrolled hypertension

Hyperthyroidism or thyrotoxicosis

Hypokalemia or electrolyte imbalances

Known hypersensitivity to clenbuterol or sympathomimetic amines

Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors

Pregnancy or breastfeeding

Quality Checklist

Good Signs

Pharmaceutical-grade tablets from a licensed manufacturer (e.g., Sopharma Clenbuterol 0.02 mg)

Consistent tablet weight, coloring, and markings indicating quality manufacturing standards

Proper blister packaging with lot number, expiration date, and manufacturer information

Purchased from a licensed pharmacy with valid prescription (where approved for human use)

Warning Signs

Research chemical liquid formulations with unverified concentrations

Tablets without pharmaceutical-grade markings or from unknown manufacturers

Products marketed at unusual dosages (e.g., 200 mcg tablets) not consistent with standard formulations

Bad Signs

Unlabeled or improperly labeled tablets with no manufacturer identification

Liquid preparations with visible particles, unusual color, or inconsistent dosing

Product sourced with no third-party testing or certificate of analysis

Any product causing effects dramatically inconsistent with expected dose-response

Frequently Asked Questions

Why do I get severe muscle cramps on clenbuterol?

Clenbuterol depletes intracellular taurine levels, which is the primary cause of muscle cramps (particularly in calves, forearms, and back). Supplementing with 3-5 grams of taurine daily significantly reduces or eliminates cramping. Adequate hydration and electrolytes (potassium, magnesium) also help. Taurine supplementation is considered standard during any clen cycle.

Can I use clenbuterol continuously or must I cycle it?

You should cycle it. Clenbuterol causes beta-2 receptor downregulation within 2-3 weeks of continuous use, dramatically reducing thermogenic efficacy. The standard 2 weeks on/2 weeks off protocol prevents this. Alternatively, add ketotifen (1-2 mg nightly) at week 2 to upregulate receptors and allow continuous use for 6-8 weeks.

Is the tremor from clenbuterol permanent?

No. Hand tremors peak around day 3-5 of starting clenbuterol, then typically diminish significantly as the body adjusts, though they rarely disappear entirely. Using a beta-blocker is contraindicated since it would block clenbuterol's desired effects. The tremors subside within 2-4 days of discontinuation.

Why do I feel worse on clenbuterol's off weeks?

During off weeks, metabolic rate returns toward baseline, and users often report increased appetite and lethargy. Some take ephedrine/caffeine during these periods as a lower-potency alternative thermogenic to maintain some fat-loss momentum and mood support while allowing clenbuterol receptor recovery.

References

Early characterization of clenbuterol's thermogenic properties demonstrating significant increases in metabolic rate and thermogenesis in animal models, establishing the pharmacological basis for its use as a fat loss agent.

Comprehensive review of clenbuterol's pharmacology, pharmacokinetics, and clinical use as a bronchodilator. Established the oral bioavailability, half-life (~36 hours), and therapeutic dosing range for respiratory indications.

Case report documenting serious cardiac arrhythmias following clenbuterol overdose, including supraventricular tachycardia and atrial fibrillation. Highlights the cardiovascular risks of clenbuterol misuse and the importance of dose limitation.

Demonstrated that clenbuterol increases lean body mass and decreases fat mass through beta-2 receptor-mediated pathways. Showed dose-dependent effects on protein synthesis and muscle fiber composition in animal models.

Review of clenbuterol contamination in the food supply from its illicit use in livestock repartitioning. Documented cases of food poisoning outbreaks and established the basis for regulatory bans on clenbuterol in animal husbandry across the EU and many other jurisdictions.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.